SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff in AI neocloud stocks, fueled by concerns about debt, financing costs and the sustainability of data-center spending, is weighing on Nebius alongside CoreWeave-related credit fears. Traders are split between calling NBIS oversold and expecting a rebound, and warning that sector pressures could drive further declines; some argue Nebius has a stronger balance sheet than peers.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

S&P 500 futures surged after a tech-led selloff, prompting traders to debate whether the rebound ahead of major tech earnings is a genuine recovery or a short-covering bounce that could fade. The move also undercut Black Monday anniversary fears, though many remain wary that the futures rally may not hold at the market open.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data are driving attention, especially mature results for lifileucel plus pembrolizumab in frontline melanoma, where traders highlight durable responses and progression-free survival as support for the ongoing Phase 3 trial. Reactions are mixed: some view the results as encouraging confirmation, while others say the small cohort and overlap with earlier data limit the news; early sarcoma results are also being discussed as promising but preliminary.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid steep selling pressure, with traders focused on scheduled insider share unlocks and a broader AI and semiconductor-sector downturn; concerns about its high valuation, growth and reliance on major customers add to the bearish case. Some investors see the selloff as an oversold buying opportunity, while others expect further declines and debate how much is due to lockup-related supply versus weak sector sentiment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders watching for the 80th death event that triggers final analysis after the last disclosed count of 78; the prolonged wait and company silence have fueled speculation about unusually long patient survival and possible ASH data, but those interpretations remain unconfirmed. The debate is reflected in bullish expectations for a positive readout and skepticism that the delay or conference booth signals anything, amid concern over the stocks sharp decline.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

Traders are focused on GEOMs proposed platform for tokenizing oil and mineral assets and royalties, with bulls touting a coming platform launch and a possible royalty-paying partner announcement tied to Greenland-related projects and GLND. That thesis is disputed: skeptics question the projects connections and utility, while the tokens thin liquidity and sharp declines fuel concerns about selling pressure and a potential rug pull.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech selloff has put XBI under pressure, with traders pointing to rising-rate concerns, risk aversion and rotation away from the sector rather than a single company-specific catalyst. The community is split between expecting further weakness and viewing the decline as an oversold buying opportunity, with upcoming biotech data and deal activity seen as potential supports.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules could make Strategy eligible for removal, raising concern about potential forced selling by index-tracking funds and contributing to the sharp share decline. Traders debate whether the risk is already priced in, while also weighing Bitcoins weakness and MSTRs steeper fall against dip-buying optimism.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereums sharp swings alongside a weak broader crypto market have put its ability to hold support and reclaim resistance at the center of discussion. Traders are split between viewing the rebound as a bear trap and expecting further downside, while others see dip buying and short positioning as signs of a recovery.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech-led selloff followed by a strong futures rebound has traders debating whether dip-buying and short covering signal a recovery or a bull trap. Black Monday anniversary fears added to the volatility, while upcoming mega-cap earnings are seen as a test for tech sentiment.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape

From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating   New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of replacing damaged or lost insulin-producing cells sounded more like a long-term scientific goal than a practical treatment strategy. That is […]
The post Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape appeared first on Financial News Media.

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin Compounds

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin Compounds Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin...

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences Lakewood-Amedex Biotherapeutics Announces Participation in October ConferencesPR NewswireSARASOTA, Fla., Oct. 1, 2026SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the...

LABT’s Nu-3 Takes Aim at Resistant Foot Infections as Phase 2 Catalyst Looms

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is heading deeper into the clinical stage with its lead antimicrobial candidate Nu-3, and fresh laboratory data are giving the company another potential catalyst as its Phase 2a trial gets underway.

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 28, 2026 Lead...

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot UlcersPR NewswireSARASOTA, Fla., Sept. 24...

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3PR NewswireSARASOTA, Fla., Sept. 21...

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of...

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SARASOTA, Fla., Sept. 8, 2026 SARASOTA, Fla., Sept. 8, 2026 /PRNewswire...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million.
Lakewood-Amedex (NASDAQ:LABT)read more...

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Lakewood-Amedex Biotherapeutics Inc.

This Newly Listed Biotech Is Soaring – Retail Says $14 Is The Line In The Sand

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.58
Prev Close	$0.6124
Open	$0.63
Dividend Yield	N/A
50-Day Moving Average	$1.77
Beta	0.52
Avg. Volume	2.33M
PE Ratio	-0.06

52-Week High	$98.20
52-Week Low	$0.58
Market Capitalization	$1.37M
EPS (Annual)	-$8.40
Price to Book	0.29
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

LABT Fundamentals